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Introduction
Citrate is the recommended anticoagulant for continu-
ous renal replacement therapy (RRT) [1], and is thought
to confer numerous benefits, including more continuous
hours of filtration, fewer total circuits used, less overall
cost and maybe improved patient and kidney survival
when compared with heparin anticoagulation [2]. Citrate
is run pre filter, calcium is infused post filter, the rates
of both determined by the filter and patient ionised cal-
cium level respectively. This is monitored by blood tests,
which must be sampled frequently. Filter and patient
ionised calcium levels, citrate and calcium infusion
rates, are recorded as part of clinical practice at RSCH.
The target plasma ionised calcium concentration is 1.0 -
1.2mM, the target filter ionised calcium concentration is
0.25 - 0.5mM.
Objectives
There are currently little data available on how often the
rates of citrate and calcium infusion are changed, and
consequently some concern amongst nursing staff
regarding the frequency of blood sampling and associated
workload.
Methods
Observational data were recorded on the time intervals
between the changes in the calcium chloride, and citrate
infusion rate. Data were collected prospectively for the
first five patients, up to and including the first 15 days
following citrate introduction.
Results
Data from the first five patients filtered with citrate
are presented, representing a total of 736 hours of
RRT. The median length of time of citrate infusion
between dose changes was 32 hours (interquartile
range 7.0 - 52.2 hours), with the longest period 112.7
hours. The median length of time of calcium infusion
between dose changes was 6.3 hours (interquartile
range 2.0 - 20.0 hours) with the longest period 96.5
hours (Figure 1).
Conclusions
When citrate anticoagulation is used for renal replace-
ment therapy, there are long periods when neither citrate
nor calcium infusion rates require altering. These long
periods often follow a small cluster of dose changes, as a
‘steady state’ is achieved. As a result, blood samples are
required less frequently, which in turn, contributes to a
lighter workload for nursing staff and lower operational
costs.
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Figure 1 Box Whisker Plot to show hours between dose
changes of citrate (1) and calcium (2). Boxes represent the
interquartile range and median, whiskers represent the
minimum and maximum time interval (hours).
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